Low 21-gene expression score associated with low risk of breast cancer recurrence
the ONA take:
Patients with hormone receptor-positive, HER2-negative, axillary node-negative breast cancer and a favorable 21-gene expression assay score had very low rates of disease recurrence at 5 years with endocrine therapy alone, initial results of the TAILORx study published online ahead of print in The New England Journal of Medicine have shown.
For the study, 10,253 eligible women with breast cancer were enrolled. Of those, 1,626 women had a recurrence score of 0 to 10 who were assigned to receive endocrine therapy alone without chemotherapy.
Results showed that 5-year invasive disease-free survival rate was 93.8% (95% CI: 92.4, 94.9), the rate of freedom from recurrence of breast cancer at a distant site was 99.3% (95% CI: 98.7, 99.6), and the rate of freedom from recurrence at a distant or local-regional site was 98.7%. Researchers found that the overall survival rate was 98.0% (95% CI: 97.1, 98.6).
"The compelling results seen in this global study provide unequivocal evidence supporting the clinical utility of Oncotype DX to risk-stratify patients with early stage breast cancer, and indicate that the findings are generalizable to everyday clinical practice," said lead author Joseph A. Sparano, MD, vice-chairman of medical oncology at Montefiore Einstein Center for Cancer Care, and professor of medicine and of obstetrics, gynecology, women's health at Albert Einstein College of Medicine.
Patients with HER2-negative, axillary node-negative breast cancer and favorable 21-gene expression assay score had low rates of recurrence.
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Behavior Pain Assessment Tool Measures Pain In Patients Who Cannot Communicate Verbally
- Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Updated ASTRO Guideline Bolsters Safety, Efficacy of Palliative RT for Bone Metastases
- Thyroid Cancer Incidence Increasing Among Younger, Hispanic, African American Populations
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Recommendations Against Contralateral Prophylactic Mastectomy Not Tied to Patient Satisfaction
- Self-efficacy Level Predictive of Likelihood to Follow Through With Colorectal Cancer Screening
- Chronic Myeloproliferative Neoplasms Treatment (Fact Sheet)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|